Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note

Zoetis (ZTS) fell 2.22% to $71.40 in a session where broader markets posted gains, signaling relative weakness in the animal health name. The stock's underperformance comes as Zacks Investment Research projects a 10.59% decline in earnings per share and a 3.66% revenue decline for the upcoming quarter.

Despite trading at a discount to its industry average on a forward P/E basis, Zoetis carries a Zacks Rank of #5 (Strong Sell), reflecting deteriorating analyst sentiment. The double-digit EPS contraction paired with revenue decline suggests headwinds beyond normal cyclical pressure in the animal health sector.

The magnitude of the projected EPS decline—more than double the revenue drop—points to margin compression or increased operating costs. The stock's failure to participate in the broader market rally amplifies the bearish signal embedded in the downgrade.